Product Description
YL205 is built on the TMALIN platform, which is comprised of an anti-NaPi2b humanized monoclonal antibody and conjugated in a site-specific manner to yield a uniform DAR 8 product. NaPi2b, encoded by the SLC34A2 gene, is a cell surface sodium-dependent phosphate transporter that is highly expressed in certain cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. (Sourced from: https://aacrjournals.org/cancerres/article/84/6_Supplement/1894/736333/Abstract-1894-Preclinical-development-of-YL205-a)
Mechanisms of Action: NPT-iib Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jilin Cancer Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate YL205 in Patients with Advanced Solid Tumors | N/A |
Not yet recruiting |
Endometrial Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Kidney Cancer |
2026-07-10 |
|
| CTR20241918 | N/A |
Unknown |
Oncology Solid Tumor Unspecified |
None |